MONTREAL, July 20, 2016 /CNW Telbec/ - SNC-Lavalin (TSX: SNC) announced today that it has been awarded a $12.5 million contract by Medicago to provide design services for a new production facility in Quebec City, Canada.
The facility will regroup Medicago's head office and consolidate all its current Canadian operations. The headquarters will house research and development activities and commercial production in the city's Espace d'innovation D'Estimauville (Estimauville innovation park).
With construction expected to begin in the fall of 2016, SNC-Lavalin will perform preliminary and detailed engineering services, procurement of equipment critical to the process fabrication and the complete supply of automation integration services. Once complete, the 44,000-M², fully automated facility will house manufacturing, offices, laboratories, a greenhouse, a pilot plant and support services.
"Our relationship with Medicago dates back to 2008," said Ian L. Edwards, President, Infrastructure, SNC-Lavalin. "We are very proud to be part of a local project that, once complete, will export vaccines to foreign markets and help Canada meet its seasonal and pandemic flu vaccine needs."
Founded in 1911, SNC-Lavalin is one of the leading engineering and construction groups in the world and a major player in the ownership of infrastructure. From offices in over 50 countries, SNC-Lavalin's employees are proud to build what matters. Our teams provide Engineering, Procurement and Construction (EPC) and Engineering, Procurement, Construction and Management (EPCM) services to clients in a variety of industry sectors, including oil and gas, mining and metallurgy, infrastructure and power. SNC-Lavalin can also combine these services with its financing and operations and maintenance capabilities to provide complete end-to-end project solutions.www.snclavalin.com
For further information: Media: Louis-Antoine Paquin, Manager, Media Relations, 514-393-8000, ext. 54772, [email protected]; Investors: Denis Jasmin, Vice President, Investor Relations, 514-393-8000, ext. 57553, [email protected]